View Older Stories View More Recent Stories
-
Danaher (DHR) appoints Greg Milosevich to EVP, Life Sciences
-
Askeladden Capital Shares Primary Research with AstroNova Shareholders
-
Danaher (DHR) Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Askeladden Capital Presents Plan To Maximize AstroNova's Shareholder Value
-
Stifel Reiterates Buy Rating on Danaher (DHR)
-
Danaher (DHR) PT Raised to $248 at TD Cowen as '1Q Strikes Many Positive Chords'
-
Danaher (DHR) PT Raised to $215 at Barclays
-
Danaher (DHR) PT Lowered to $260 at JPMorgan
-
Danaher (DHR) PT Lowered to $230 at Jefferies
-
Danaher (DHR) Tops Q1 EPS by 26c; initiates guidance
-
Danaher (DHR) call put ratio 1.8 calls to 1 put into quarter results
-
Danaher (DHR) Danaher (NYSE: DHR) call put ratio 1 call to 1.4 puts into quarter results
-
Barclays Upgrades Danaher (DHR) to Overweight
-
TD Cowen: 'Danaher (DHR) Is Our Top Idea'; PT Lowered to $240
-
Evercore Adds 7 Names to Tactical Outperform List
-
Goldman Sachs Upgrades Danaher (DHR) to Buy
-
Stifel Upgrades Danaher (DHR) to Buy
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Citi Opens 90-Day Upside Short-Term View on Danaher (DHR)
-
TD Cowen Issues Stock Conclusions Following Bioproduction Market Survey
-
Danaher (DHR) Appoints Charles Lamanna to its Board
-
Danaher (DHR) Declares $0.32 Quarterly Dividend; 0.6% Yield
-
Raymond James Downgrades Danaher (DHR) to Market Perform
-
Danaher (DHR) PT Lowered to $260 at TD Cowen as 'Weak Guide Spoils 4Q'
-
Danaher (DHR) PT Lowered to $260 at Stifel
-
Danaher (DHR) PT Lowered to $277 at RBC Capital, Reflecting Lowered FY'25/26 Estimates
-
Danaher (DHR) call put ratio 1.9 calls to 1 put with a focus on February 235 and 245 calls as share price down 9%
-
Danaher (DHR) PT Lowered to $265 at BofA Securities
-
Danaher (DHR) Misses Q4 EPS by 1c, offers guidance
-
Danaher (DHR) call put ratio 1.4 calls to 1 put into quarter results
-
Danaher (DHR) call put ratio 1.2 calls to 1 put into quarter results
-
TD Cowen: 'Assessing Impact of US Ban on China Exports for LCMS & Flow Cyt Instruments'
-
Danaher (DHR) call put ratio 1 call to 2.2 puts with a focus on January 235 puts
-
Waters Corp. (WAT), Others Decline on Concerns about New Export Controls on Biotech Equipment
-
Danaher (DHR) CEO to Comment on Financial Performance
-
Guggenheim Starts Danaher (DHR) at Buy
-
Wolfe Research Upgrades Danaher (DHR) to Outperform
-
Wolfe Research Upgrades Danaher (DHR) to Outperform
-
Danaher (DHR) PT Raised to $310 at KeyBanc
-
Danaher (DHR) PT Raised to $315 at TD Cowen
-
Danaher (DHR) PT Lowered to $277 at Baird
-
Danaher (DHR) PT Lowered to $275 at Leerink Partners
-
Danaher (DHR) Tops Q3 EPS by 14c; offers outlook
-
Danaher (DHR) October 25 weekly call option implied volatility into quarter results
-
Danaher (DHR) call put ratio 1.4 calls to 1 put into quarter results
-
Danaher (DHR) call put ratio 4.9 calls to 1 put with focus on December 280 calls into quarter results
-
TD Cowen Reiterates Buy Rating on Danaher (DHR)
-
Danaher (DHR) Confirms Third Quarter and Full Year 2024 Guidance
-
Danaher (DHR) PT Raised to $310 at TD Cowen

